Originally published as JCO Early Release 10.1200/JCO.2007.14.0988 on March 10 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O'Donnell, A. Articles by Judson, I. Search for Related Content PubMed PubMed Citation Articles by O'Donnell, A. Articles by Judson, I. Related Articles Related Articles Related Editorial Social Bookmarking                            What's this?

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Anne O'Donnell, Sandrine Faivre, Howard A. Burris, III, Daniel Rea, Vassiliki Papadimitrakopoulou, Nicholas Shand, Heidi A. Lane, Katharine Hazell, Ulrike Zoellner, John M. Kovarik, Cathryn Brock, Suzanne Jones, Eric Raymond, Ian Judson

From the Royal Marsden Hospital, Sutton, Surrey; Queen Elizabeth Hospital, Birmingham, United Kingdom; Institut Gustave-Roussy, Villejuif, France; Sarah Cannon Research Institute, Nashville, TN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Novartis Pharma AG; and Novartis Institutes for BioMedical Research, Oncology, Basel, Switzerland

Corresponding author: Anne O'Donnell, MBChB, FRACP, Wellington Cancer Centre, Capital and Coast Health Ltd, Riddiford St, Private Bag 7902, Wellington, New Zealand; e-mail: anne.o'donnell{at}ccdhb.org.nz

Purpose To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001).

Methods We performed a dose-escalation study in advanced cancer patients administering oral everolimus 5 to 30 mg/wk, with pharmacokinetic (PK) and pharmacodynamic (PD) studies. PD data prompted investigation of 50 and 70 mg weekly and daily dosing at 5 and 10 mg.

Results Ninety-two patients were treated. Dose-limiting toxicity was seen in one patient each at 50 mg/wk (stomatitis and fatigue) and 10 mg/d (hyperglycemia); hence, the maximum-tolerated dose was not reached. S6 kinase 1 activity in peripheral-blood mononuclear cells was inhibited for at least 7 days at doses 20 mg/wk. Area under the curve increased proportional to dose, but maximum serum concentration increased less than proportionally at doses 20 mg/wk. Terminal half-life was 30 hours (range, 26 to 38 hours). Partial responses were observed in four patients, and 12 patients remained progression free for 6 months, including five of 10 patients with renal cell carcinoma.

Conclusion Everolimus was satisfactorily tolerated at dosages up to 70 mg/wk and 10 mg/d with predictable PK. Antitumor activity and PD in tumors require further clinical investigation. Doses of 20 mg/wk and 5 mg/d are recommended as appropriate starting doses for these studies.

published online ahead of print at www.jco.org on March 10, 2008.

Supported by Novartis Pharma AG.

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Articles

• Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
  Chiaki Tanaka, Terence O’Reilly, John M. Kovarik, Nicholas Shand, Katharine Hazell, Ian Judson, Eric Raymond, Sabine Zumstein-Mecker, Christine Stephan, Anne Boulay, Marc Hattenberger, George Thomas, and Heidi A. Lane
  JCO 2008 26: 1596-1602 [Abstract] [Full Text]
• Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
  Josep Tabernero, Federico Rojo, Emiliano Calvo, Howard Burris, Ian Judson, Katharine Hazell, Erika Martinelli, Santiago Ramon y Cajal, Suzanne Jones, Laura Vidal, Nicholas Shand, Teresa Macarulla, Francisco Javier Ramos, Sasa Dimitrijevic, Ulrike Zoellner, Pui Tang, Michael Stumm, Heidi A. Lane, David Lebwohl, and José Baselga
  JCO 2008 26: 1603-1610 [Abstract] [Full Text]

Related Editorial

• Dose Selection in Phase I Studies: Why We Should Always Go for the Top
  Stefan Sleijfer and Erik Wiemer
  JCO 2008 26: 1576-1578 [Full Text]

This article has been cited by other articles:

				T. B. Dorff, A. Goldkorn, and D. I. Quinn Review: Targeted therapy in renal cancer Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 183 - 205. [Abstract] [PDF]

				I. Okamoto, T. Doi, A. Ohtsu, M. Miyazaki, A. Tsuya, K. Kurei, K. Kobayashi, and K. Nakagawa Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors Jpn. J. Clin. Oncol., September 25, 2009; (2009) hyp120v1. [Abstract] [Full Text] [PDF]

				S. L. Ellard, M. Clemons, K. A. Gelmon, B. Norris, H. Kennecke, S. Chia, K. Pritchard, A. Eisen, T. Vandenberg, M. Taylor, et al. Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163 J. Clin. Oncol., September 20, 2009; 27(27): 4536 - 4541. [Abstract] [Full Text] [PDF]

				J. Baselga, V. Semiglazov, P. van Dam, A. Manikhas, M. Bellet, J. Mayordomo, M. Campone, E. Kubista, R. Greil, G. Bianchi, et al. Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., June 1, 2009; 27(16): 2630 - 2637. [Abstract] [Full Text] [PDF]

				F. Meric-Bernstam and A. M. Gonzalez-Angulo Targeting the mTOR Signaling Network for Cancer Therapy J. Clin. Oncol., May 1, 2009; 27(13): 2278 - 2287. [Abstract] [Full Text] [PDF]

				M. Breuleux, M. Klopfenstein, C. Stephan, C. A. Doughty, L. Barys, S.-M. Maira, D. Kwiatkowski, and H. A. Lane Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition Mol. Cancer Ther., April 1, 2009; 8(4): 742 - 753. [Abstract] [Full Text] [PDF]

				N. Y. Lee, H.-K. Choi, J.-H. Shim, K.-W. Kang, Z. Dong, and H. S. Choi The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation Carcinogenesis, April 1, 2009; 30(4): 671 - 681. [Abstract] [Full Text] [PDF]

				B. M. Wolpin, A. F. Hezel, T. Abrams, L. S. Blaszkowsky, J. A. Meyerhardt, J. A. Chan, P. C. Enzinger, B. Allen, J. W. Clark, D. P. Ryan, et al. Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer J. Clin. Oncol., January 10, 2009; 27(2): 193 - 198. [Abstract] [Full Text] [PDF]

				P. A. Dennis Rapamycin for Chemoprevention of Upper Aerodigestive Tract Cancers Cancer Prevention Research, January 1, 2009; 2(1): 7 - 9. [Full Text] [PDF]

				R. Czerninski, P. Amornphimoltham, V. Patel, A. A. Molinolo, and J. S. Gutkind Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model Cancer Prevention Research, January 1, 2009; 2(1): 27 - 36. [Abstract] [Full Text] [PDF]

				S. R.D. Johnston Role of the mTOR Pathway in Endocrine-resistant Breast Cancer -- Opportunities for Novel Combination Strategies ASCO Educational Book, January 1, 2009; 2009(1): 20 - 28. [Abstract] [Full Text] [PDF]

				L.-Z. Liu, J. Z. Zheng, X.-R. Wang, and B.-H. Jiang Endothelial p70 S6 Kinase 1 in Regulating Tumor Angiogenesis Cancer Res., October 1, 2008; 68(19): 8183 - 8188. [Abstract] [Full Text] [PDF]

				I. E. Haines Dose Selection in Phase I Studies: Why We Should Always Go for the Most Effective J. Clin. Oncol., July 20, 2008; 26(21): 3650 - 3652. [Full Text] [PDF]

				S. Sleijfer and E. Wiemer Dose Selection in Phase I Studies: Why We Should Always Go for the Top J. Clin. Oncol., April 1, 2008; 26(10): 1576 - 1578. [Full Text] [PDF]

				C. Tanaka, T. O'Reilly, J. M. Kovarik, N. Shand, K. Hazell, I. Judson, E. Raymond, S. Zumstein-Mecker, C. Stephan, A. Boulay, et al. Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data J. Clin. Oncol., April 1, 2008; 26(10): 1596 - 1602. [Abstract] [Full Text] [PDF]